Fresenius Medical Care Corporation (NYSE:FMS) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Monday, July 31st.
FMS has been the subject of several other research reports. UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $44.00 price target on shares of Fresenius Medical Care Corporation in a research report on Tuesday, May 30th. DZ Bank AG reiterated a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, May 29th. Finally, Zacks Investment Research downgraded Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a research note on Friday, May 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company. Fresenius Medical Care Corporation currently has an average rating of “Hold” and an average price target of $48.67.
Fresenius Medical Care Corporation (NYSE FMS) traded down 0.19% during trading on Monday, reaching $46.38. 101,389 shares of the company traded hands. Fresenius Medical Care Corporation has a 52 week low of $38.05 and a 52 week high of $50.22. The firm has a market capitalization of $28.46 billion, a price-to-earnings ratio of 20.34 and a beta of 0.47. The company’s 50-day moving average price is $47.31 and its 200 day moving average price is $44.97.
Fresenius Medical Care Corporation (NYSE:FMS) last issued its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The business had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the firm posted $0.96 EPS. Fresenius Medical Care Corporation’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts expect that Fresenius Medical Care Corporation will post $2.33 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/bidaskclub-lowers-fresenius-medical-care-corporation-fms-to-hold-updated-updated.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Harding Loevner LP increased its position in Fresenius Medical Care Corporation by 7.1% in the first quarter. Harding Loevner LP now owns 3,528,960 shares of the company’s stock worth $148,675,000 after buying an additional 233,347 shares in the last quarter. Cambiar Investors LLC raised its stake in Fresenius Medical Care Corporation by 8.1% in the first quarter. Cambiar Investors LLC now owns 2,516,416 shares of the company’s stock valued at $106,017,000 after buying an additional 188,019 shares during the last quarter. Karp Capital Management Corp bought a new stake in Fresenius Medical Care Corporation during the first quarter valued at $7,887,000. Renaissance Technologies LLC bought a new stake in Fresenius Medical Care Corporation during the first quarter valued at $7,141,000. Finally, Bank of America Corp DE raised its stake in Fresenius Medical Care Corporation by 12.1% in the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock valued at $62,917,000 after buying an additional 161,262 shares during the last quarter. Hedge funds and other institutional investors own 2.81% of the company’s stock.
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
What are top analysts saying about Fresenius Medical Care Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care Corporation and related companies.